0000000000414608

AUTHOR

Marisa Blasco

showing 2 related works from this author

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

2020

Background There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. Methods We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assesse…

Pulmonary and Respiratory MedicineAdultMaleARDSmedicine.medical_treatmentSeverity of Illness IndexDexamethasonelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawFraction of inspired oxygenIntensive careSeverity of illnessmedicineData monitoring committeeHumans030212 general & internal medicineGlucocorticoidsDexamethasoneAgedMechanical ventilationRespiratory Distress Syndromebusiness.industryMiddle Agedmedicine.diseaseRespiration ArtificialIntensive Care UnitsTreatment Outcome030228 respiratory systemAnesthesiaAdministration IntravenousFemalebusinessmedicine.drug
researchProduct

Usefulness of C-reactive protein and left ventricular function for risk assessment in survivors of acute myocardial infarction.

2004

The additional prognostic information provided by C-reactive protein (CRP) to parameters of left ventricular function in survivors of acute myocardial infarction (AMI) was investigated in 665 patients (326 with ST elevation and 339 with non-ST elevation). Cox multivariable analysis identified the following predictors of 6-month cardiac death: age (per 5 years hazard ratio [HR] 1.2, 95% confidence interval [CI] 1.1 to 1.4, p = 0.004), Killip class >I at presentation (HR 2.4, 95% CI 1.3 to 4.5, p = 0.0001), a reduced ejection fraction (per 5% HR 1.3, 95% CI 1.2 to 1.4, p = 0.0001), and greater CRP (per 5 mg/L HR 1.02, 95% CI 1.01 to 1.04, p = 0.02); the C-index of the model was 0.77 without a…

Malemedicine.medical_specialtyMyocardial InfarctionRisk AssessmentVentricular Dysfunction LeftPredictive Value of TestsInternal medicineMedicineHumansMyocardial infarctionKillip classAgedProportional Hazards ModelsEjection fractionChi-Square Distributionbiologybusiness.industryProportional hazards modelST elevationHazard ratioC-reactive proteinmedicine.diseasePrognosisConfidence intervalC-Reactive ProteinMultivariate AnalysisCardiologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesThe American journal of cardiology
researchProduct